Blake Gurfein
Chief Tech/Sci/R&D Officer bei TIVIC HEALTH SYSTEMS, INC.
Vermögen: 1 400 $ am 31.03.2024
Profil
Blake Gurfein is currently the Chief Scientific Officer at Tivic Health Systems, Inc. He previously held the same position at Rio Grande Neurosciences, Inc. from 2014 to 2017.
Gurfein received his undergraduate degree from Brown University and his doctorate from Icahn School of Medicine at Mount Sinai.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
20.03.2024 | 1 120 ( 0,08% ) | 1 400 $ | 31.03.2024 |
Aktive Positionen von Blake Gurfein
Unternehmen | Position | Beginn |
---|---|---|
TIVIC HEALTH SYSTEMS, INC. | Chief Tech/Sci/R&D Officer | 01.03.2019 |
Ehemalige bekannte Positionen von Blake Gurfein
Unternehmen | Position | Ende |
---|---|---|
Rio Grande Neurosciences, Inc.
Rio Grande Neurosciences, Inc. Hospital/Nursing ManagementHealth Services Rio Grande Neurosciences, Inc. offers neurological and psychiatric therapies. It focuses on developing, acquiring, and licensing non-invasive brain stimulation therapies used to treat pathologies of the central nervous system. The company was founded in 2011 and is headquartered in Santa Fe, NM. | Chief Tech/Sci/R&D Officer | 01.01.2017 |
Ausbildung von Blake Gurfein
Brown University | Undergraduate Degree |
Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
TIVIC HEALTH SYSTEMS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Rio Grande Neurosciences, Inc.
Rio Grande Neurosciences, Inc. Hospital/Nursing ManagementHealth Services Rio Grande Neurosciences, Inc. offers neurological and psychiatric therapies. It focuses on developing, acquiring, and licensing non-invasive brain stimulation therapies used to treat pathologies of the central nervous system. The company was founded in 2011 and is headquartered in Santa Fe, NM. | Health Services |